Form 4: Alkermes Director Richard Gaynor Awarded Equity Compensation

Alkermes plc Director Richard Gaynor has been granted non-qualified stock options and restricted stock units as part of his compensation, aligning his interests with shareholders.

Summary

• Richard Gaynor, a Director of Alkermes plc, was granted 13,474 non-qualified stock options on May 21, 2025, with an exercise price of $30.53 per share.
• These stock options will vest in full on May 21, 2026, and have an expiration date of May 21, 2035.
• Additionally, Mr. Gaynor received an award of 6,142 Restricted Stock Units (RSUs) on May 21, 2025.
• Each RSU represents a contingent right to receive one ordinary share of Alkermes plc.
• The Restricted Stock Units are scheduled to vest in full on May 21, 2026.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the equity grant aligns the director's interests with shareholders, which is a good governance practice. However, it is a routine compensation event and not indicative of a major new development or financial performance.

Positives

• The granting of equity awards to Director Richard Gaynor aligns his financial interests directly with those of the company's shareholders, incentivizing long-term performance.
• The awards are part of a standard compensation package for directors, indicating routine corporate governance practices.

Industry Context

The granting of equity compensation, such as stock options and restricted stock units, to directors is a common and widely accepted practice across various industries, including the pharmaceutical and biotechnology sectors. This method of compensation is designed to align the interests of the board members with the long-term performance and shareholder value creation of the company.

Comparison to Industry Standards

• The structure of this equity award, involving both stock options and restricted stock units with a vesting period, is consistent with typical director compensation packages observed in publicly traded companies within the biotechnology and pharmaceutical industries.
• Companies like Biogen Inc. (BIIB) and Gilead Sciences, Inc. (GILD) also frequently utilize similar equity-based incentives for their non-employee directors to foster long-term commitment and performance alignment.

Stakeholder Impact

• Shareholders: The equity awards align the director's interests with shareholders, potentially leading to better long-term decision-making focused on increasing shareholder value.

Next Steps

• The non-qualified stock options and restricted stock units are scheduled to vest on May 21, 2026.

Key Dates

Keywords

Alkermes, ALKS, Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Equity Compensation, Director Compensation, Beneficial Ownership